OKYO Pharma Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for OKYO Pharma stock have an average target of 7.00, which predicts an increase of 351.61% from the current stock price of 1.55.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$7.00	$7.00	$7.00
Change	+351.61%	+351.61%	+351.61%	+351.61%

* Price targets were last updated on Apr 13, 2026.

Analyst Ratings

The average analyst rating for OKYO Pharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	2
Buy	0	0	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	4	4	4	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $7	Buy	Maintains	$7	+351.61%	Apr 13, 2026
Yi Chen H.C. Wainwright	H.C. Wainwright	Buy Reiterates $7	Buy	Reiterates	$7	+351.61%	Jan 29, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.10

EPS Next Year

-0.20

from -0.10

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-0.32	-0.36	-0.60	-0.57	-0.12	-0.22	-0.31
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-	-
Avg	-0.10	-0.20
Low	-	-

EPS Growth

EPS Growth	2027	2028
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.